3 documents found, page 1 of 1
Decompressive surgery in cerebral venous sinus thrombosis due to vaccine‐induce...
Krzywicka, Katarzyna; de Sousa, Diana Aguiar; Cordonnier, Charlotte; Bode, Felix J.; Field, Thalia S.; Michalski, Dominik; Pelz, Johann; Skjelland, MonaBackground and purpose: Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is an adverse drug reaction occurring after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. CVST-VITT patients often present with large intracerebral haemorrhages and a high proportion undergoes decompressive surgery. Clinical characteristics, therapeutic manag...
Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immu...
Weller, Johannes; Krzywicka, Katarzyna; van de Munckhof, Anita; Dorn, Franziska; Althaus, Katharina; Bode, Felix J.; Bandettini di Poggio, MonicaIntroduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT. Patients and methods: We report data from an international registry of patients who developed CVST within 28 days of SARS...
Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination
Scutelnic, Adrian; Krzywicka, Katarzyna; Mbroh, Joshua; van de Munckhof, Anita; van Kammen, Mayte Sánchez; de Sousa, Diana Aguiar; Lindgren, ErikObjective: Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance...